Share Price and Basic Stock Data
Last Updated: October 16, 2025, 6:36 pm
| PEG Ratio | 2.25 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Beryl Drugs Ltd operates within the pharmaceutical sector, showcasing a market capitalization of ₹11.2 Cr and a price per share of ₹22.0. The company reported a notable increase in sales, which rose to ₹26.84 Cr for the fiscal year ending March 2023, up from ₹14.48 Cr in March 2022. This growth trajectory continued with sales of ₹26.72 Cr in March 2024. However, preliminary figures for March 2025 indicate a decline to ₹22.56 Cr. The quarterly sales figures reflect variability, with a peak of ₹8.19 Cr in December 2022 and a subsequent dip to ₹3.21 Cr in March 2024. The company’s operating profit margin (OPM) fluctuated significantly, recording 13.81% in June 2023 but dropping to 0.62% in March 2024. This inconsistency in revenue and profitability highlights potential challenges in maintaining stable growth amidst market fluctuations.
Profitability and Efficiency Metrics
Beryl Drugs Ltd’s profitability metrics present a mixed picture. The company reported a net profit of ₹0.58 Cr for the fiscal year 2025, a decrease from ₹0.77 Cr in 2023, indicating a contraction in earnings. The earnings per share (EPS) also fell to ₹1.14 in March 2025, compared to ₹1.52 in March 2023. The return on equity (ROE) stood at 6.30%, while the return on capital employed (ROCE) was slightly better at 10.2%. The interest coverage ratio (ICR) of 10.28x suggests a robust capacity to meet interest obligations, indicating financial prudence. However, the cash conversion cycle (CCC) of 94.23 days raises concerns about working capital efficiency, particularly when coupled with high inventory days in previous years. The operating profit margin’s volatility indicates that while Beryl Drugs has potential, it must enhance operational efficiency to stabilize its profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Beryl Drugs Ltd reflects moderate financial health, with total borrowings recorded at ₹4.07 Cr against reserves of ₹4.41 Cr. The debt-to-equity ratio appears manageable, although the company’s long-term liabilities have fluctuated over the years. The total assets stood at ₹15.96 Cr as of March 2025, down from ₹17.52 Cr in March 2023. This decline suggests potential liquidity concerns, especially in conjunction with a working capital days figure of 68.00. The company’s ability to leverage its assets efficiently is demonstrated by a ROCE of 10.15%, which, while respectable, is lower than industry standards. Furthermore, the absence of foreign institutional investment (FIIs) and domestic institutional investment (DIIs) may indicate a lack of confidence among larger investors, although public ownership remains strong at 73.61%.
Shareholding Pattern and Investor Confidence
Beryl Drugs Ltd has a diverse shareholding structure, with promoters holding 26.38% of equity as of March 2025. This level of promoter ownership suggests a commitment to the business, although the significant public shareholding of 73.61% could imply that the stock is less appealing to institutional investors. The number of shareholders has fluctuated slightly, reaching 7,415 by March 2025, indicating some stability in retail investor interest. However, the fact that FIIs and DIIs are not represented may raise questions about the company’s attractiveness to institutional investors, which is often seen as a sign of confidence in a company’s prospects. This shareholding pattern could affect stock liquidity and price stability, especially in volatile market conditions.
Outlook, Risks, and Final Insight
If margins sustain at higher levels and sales recover from the recent decline, Beryl Drugs Ltd could improve its overall financial health. However, the company faces risks including fluctuating sales performance and the need to enhance operational efficiencies to stabilize profit margins. Additionally, the lack of institutional investment may hinder long-term growth potential. If Beryl Drugs can effectively manage its cash conversion cycle and improve working capital efficiency, it may position itself better for future growth. Nonetheless, the volatility in earnings and the dependency on public shareholder sentiment will be critical factors influencing the company’s trajectory moving forward. The balance between maintaining profitability and managing operational costs will be essential for Beryl Drugs to navigate the competitive pharmaceutical landscape successfully.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Beryl Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 153 Cr. | 122 | 247/84.3 | 34.9 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,735 Cr. | 435 | 443/192 | 106 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.2 Cr. | 46.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.1 Cr. | 20.6 | 29.1/17.0 | 31.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,728.56 Cr | 1,182.89 | 50.69 | 193.63 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.97 | 7.90 | 8.19 | 6.09 | 8.18 | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.40 | 5.22 | 4.83 |
| Expenses | 4.37 | 7.27 | 7.47 | 5.82 | 7.05 | 7.37 | 6.87 | 3.19 | 5.30 | 5.08 | 4.81 | 4.72 | 4.28 |
| Operating Profit | 0.60 | 0.63 | 0.72 | 0.27 | 1.13 | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.50 | 0.55 |
| OPM % | 12.07% | 7.97% | 8.79% | 4.43% | 13.81% | 8.90% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.13 | 0.11 | 0.12 | 0.06 | 0.12 | 0.10 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.10 |
| Depreciation | 0.25 | 0.19 | 0.22 | 0.15 | 0.28 | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 |
| Profit before tax | 0.22 | 0.33 | 0.38 | 0.06 | 0.73 | 0.33 | 0.37 | -0.43 | 0.50 | 0.11 | 0.16 | 0.10 | 0.07 |
| Tax % | 0.00% | -6.06% | 60.53% | -16.67% | 27.40% | 18.18% | 16.22% | -16.28% | 26.00% | 90.91% | 62.50% | -50.00% | 71.43% |
| Net Profit | 0.22 | 0.34 | 0.14 | 0.06 | 0.53 | 0.27 | 0.31 | -0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 |
| EPS in Rs | 0.43 | 0.67 | 0.28 | 0.12 | 1.05 | 0.53 | 0.61 | -0.69 | 0.73 | 0.02 | 0.10 | 0.30 | 0.04 |
Last Updated: August 19, 2025, 10:25 pm
Below is a detailed analysis of the quarterly data for Beryl Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 4.83 Cr.. The value appears to be declining and may need further review. It has decreased from 5.22 Cr. (Mar 2025) to 4.83 Cr., marking a decrease of 0.39 Cr..
- For Expenses, as of Jun 2025, the value is 4.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.72 Cr. (Mar 2025) to 4.28 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.50 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Jun 2025, the value is 11.39%. The value appears strong and on an upward trend. It has increased from 9.58% (Mar 2025) to 11.39%, marking an increase of 1.81%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Mar 2025) to 0.38 Cr., marking an increase of 0.06 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 71.43%. The value appears to be increasing, which may not be favorable. It has increased from -50.00% (Mar 2025) to 71.43%, marking an increase of 121.43%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.04. The value appears to be declining and may need further review. It has decreased from 0.30 (Mar 2025) to 0.04, marking a decrease of 0.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 21.09 |
| Expenses | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 18.89 |
| Operating Profit | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.28 | 1.24 | 2.20 |
| OPM % | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 10.43% |
| Other Income | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 1.41 | 0.00 |
| Interest | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.42 |
| Depreciation | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 | 1.34 |
| Profit before tax | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 | 0.44 |
| Tax % | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% | |
| Net Profit | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.23 |
| EPS in Rs | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 112.50% | -364.71% | 320.00% | -40.40% | -91.53% | 380.00% | -375.00% | 216.67% | 0.00% | -24.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 182.87% | -477.21% | 684.71% | -360.40% | -51.12% | 471.53% | -755.00% | 591.67% | -216.67% | -24.68% |
Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 16% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 63% |
| 3 Years: | 42% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 29% |
| 3 Years: | 35% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: September 10, 2025, 3:11 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 |
| Borrowings | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.07 |
| Other Liabilities | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.39 |
| Total Liabilities | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
| Fixed Assets | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 |
| CWIP | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 |
| Other Assets | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 |
| Total Assets | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
Below is a detailed analysis of the balance sheet data for Beryl Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.09 Cr..
- For Reserves, as of Mar 2025, the value is 4.41 Cr.. The value appears strong and on an upward trend. It has increased from 3.83 Cr. (Mar 2024) to 4.41 Cr., marking an increase of 0.58 Cr..
- For Borrowings, as of Mar 2025, the value is 4.07 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.09 Cr. (Mar 2024) to 4.07 Cr., marking a decrease of 1.02 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2.39 Cr.. The value appears to be improving (decreasing). It has decreased from 3.48 Cr. (Mar 2024) to 2.39 Cr., marking a decrease of 1.09 Cr..
- For Total Liabilities, as of Mar 2025, the value is 15.96 Cr.. The value appears to be improving (decreasing). It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
- For Fixed Assets, as of Mar 2025, the value is 6.20 Cr.. The value appears strong and on an upward trend. It has increased from 6.17 Cr. (Mar 2024) to 6.20 Cr., marking an increase of 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 9.76 Cr.. The value appears to be declining and may need further review. It has decreased from 11.32 Cr. (Mar 2024) to 9.76 Cr., marking a decrease of 1.56 Cr..
- For Total Assets, as of Mar 2025, the value is 15.96 Cr.. The value appears to be declining and may need further review. It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
Notably, the Reserves (4.41 Cr.) exceed the Borrowings (4.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.76 | -0.99 | -1.19 | -1.78 | -0.44 | -2.22 | -4.32 | -3.67 | -4.85 | -2.54 | -2.81 | -2.83 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 |
| Inventory Days | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | |||
| Days Payable | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | |||
| Cash Conversion Cycle | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 |
| Working Capital Days | 36.90 | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 63.52 | 46.51 | 57.90 | 68.00 |
| ROCE % | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 | Mar 17 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.96 | 0.00 |
| Diluted EPS (Rs.) | 1.96 | 0.00 |
| PBDIT Margin (%) | 10.56 | 1.89 |
| PBIT Margin (%) | 8.50 | -1.38 |
| PBT Margin (%) | 7.67 | -3.12 |
| Net Profit Margin (%) | 6.21 | -3.59 |
| NP After MI And SOA Margin (%) | 6.21 | -3.59 |
| Interest Coverage Ratio (X) | 10.28 | -0.79 |
| Interest Coverage Ratio (Post Tax) (X) | 8.50 | -1.06 |
After reviewing the key financial ratios for Beryl Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For Diluted EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For PBDIT Margin (%), as of Mar 18, the value is 10.56. This value is within the healthy range. It has increased from 1.89 (Mar 17) to 10.56, marking an increase of 8.67.
- For PBIT Margin (%), as of Mar 18, the value is 8.50. This value is below the healthy minimum of 10. It has increased from -1.38 (Mar 17) to 8.50, marking an increase of 9.88.
- For PBT Margin (%), as of Mar 18, the value is 7.67. This value is below the healthy minimum of 10. It has increased from -3.12 (Mar 17) to 7.67, marking an increase of 10.79.
- For Net Profit Margin (%), as of Mar 18, the value is 6.21. This value is within the healthy range. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is 6.21. This value is below the healthy minimum of 8. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 10.28. This value is within the healthy range. It has increased from -0.79 (Mar 17) to 10.28, marking an increase of 11.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 8.50. This value is within the healthy range. It has increased from -1.06 (Mar 17) to 8.50, marking an increase of 9.56.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beryl Drugs Ltd:
- Net Profit Margin: 6.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50.7 (Industry average Stock P/E: 50.69)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 133, Kanchan Bagh, Indore Madhya Pradesh 452001 | beryldrugs25@yahoo.com http://www.beryldrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Sethi | Chairman & Director |
| Mr. Sanjay Sethi | Managing Director |
| Mr. Abhinav Naik | Independent Director |
| Mrs. Shreya Saraf | Independent Woman Director |
FAQ
What is the intrinsic value of Beryl Drugs Ltd?
Beryl Drugs Ltd's intrinsic value (as of 16 October 2025) is 48.74 which is 111.91% higher the current market price of 23.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 11.7 Cr. market cap, FY2025-2026 high/low of 43.7/17.4, reserves of ₹4.41 Cr, and liabilities of 15.96 Cr.
What is the Market Cap of Beryl Drugs Ltd?
The Market Cap of Beryl Drugs Ltd is 11.7 Cr..
What is the current Stock Price of Beryl Drugs Ltd as on 16 October 2025?
The current stock price of Beryl Drugs Ltd as on 16 October 2025 is 23.0.
What is the High / Low of Beryl Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beryl Drugs Ltd stocks is 43.7/17.4.
What is the Stock P/E of Beryl Drugs Ltd?
The Stock P/E of Beryl Drugs Ltd is 50.7.
What is the Book Value of Beryl Drugs Ltd?
The Book Value of Beryl Drugs Ltd is 18.7.
What is the Dividend Yield of Beryl Drugs Ltd?
The Dividend Yield of Beryl Drugs Ltd is 0.00 %.
What is the ROCE of Beryl Drugs Ltd?
The ROCE of Beryl Drugs Ltd is 10.2 %.
What is the ROE of Beryl Drugs Ltd?
The ROE of Beryl Drugs Ltd is 6.30 %.
What is the Face Value of Beryl Drugs Ltd?
The Face Value of Beryl Drugs Ltd is 10.0.